Rank: 109 | Score: 72/100 | Category: Translational | Disease: Amyotrophic Lateral Sclerosis
Targeting systemic metabolic dysfunction — including hypermetabolism, lipid dysregulation, and glucose intolerance — will slow ALS progression and improve survival.
Addresses the "Systemic Metabolic Dysfunction in ALS Progression" gap — specifically, whether metabolic interventions can modify disease course.
ALS involves significant systemic metabolic dysfunction:
- Hypermetabolism: ~60% of ALS patients have elevated resting energy expenditure
- Lipid alterations: Reduced HDL, elevated triglycerides correlate with faster progression
- Glucose intolerance: Insulin resistance observed in subset
- Muscle hypometabolism: Early metabolic defects in muscle
Metabolic dysfunction may be:
- A driver of progression (via energy deficit)
- A consequence (via denervation)
- Both (feedback loop)
Targeting metabolism could preserve muscle function, support neural energetics, and slow progression.
- ALS median survival is 2-4 years
- Riluzole and edaravone provide limited benefit
- Metabolic interventions are low-risk
- May preserve function even if not disease-modifying
Type: Multi-arm randomized controlled trial
Population:
- Definite or probable ALS (Awaji or revised El Escorial)
- Disease duration <24 months
- Age 18-80
- Not on metabolic drugs (metformin, statins)
Arm A (Caloric Restriction Mimetic):
- Agent: Metformin 500mg BID
- Rationale: Improves insulin sensitivity, activates AMPK, extends lifespan
Arm B (Lipid-Targeted):
- Agent: Omega-3 fatty acids (EPA+DHA 2g/day)
- Statin: Atorvastatin 20mg (if elevated LDL)
- Rationale: Lipid alterations drive progression
Arm C (Combination Metabolic):
- Metformin + Omega-3 + CoQ10 300mg
- Rationale: Multi-target metabolic support
Arm D (Control):
| Biomarker |
Timing |
Purpose |
| Fasting glucose/insulin |
Baseline, M3, M6, M12 |
Insulin sensitivity |
| HOMA-IR |
Baseline, M6, M12 |
Metabolic status |
| Lipid panel |
Baseline, M3, M6, M12 |
Lipid status |
| Resting energy expenditure (REE) |
Baseline, M6 |
Metabolic rate |
| Body composition (DEXA) |
Baseline, M6, M12 |
Muscle/fat |
| Creatinine |
Baseline, M6, M12 |
Muscle mass |
n=320 (80 per arm)
- Power: 80% to detect 25% slower ALSFRS-R decline
- Alpha: 0.05
- Accounting for 15% attrition
24 months
- Interim analysis at 12 months
- Primary endpoint at 24 months
- SOD1G93A mouse metabolic profiling
- Zebrafish muscle metabolism models
- iPSC motor neurons with metabolic defects
- Muscle biopsy metabolic assays
- Fibroblast bioenergetics (Seahorse)
- Lipidomics
- ALSFRS-R slope at 24 months
- Comparing metabolic arms to control
- Survival: Time to death/tracheostomy
- FVC decline: Respiratory function
- Body weight: Nutritional status
- Quality of life: ALSAQ-40
- Combination metabolic therapy slows ALSFRS-R by 2-4 points
- May improve survival by 3-6 months
- Best response in hypermetabolic subgroup
- All agents generic and available
- Metabolic monitoring standard
- Low-risk interventions
| Component |
Cost |
| Study drug |
$800/patient |
| Metabolic testing |
$1,400/patient |
| Clinical visits |
$2,400/patient |
| DEXA/imaging |
$600/patient |
| Total |
$5,200/patient |
| Project total |
$1.7M |
- Preparation: 6 months
- Enrollment: 12 months
- Follow-up: 12 months
- Analysis: 3 months
- Total: 33 months
¶ Risks and Mitigations
| Risk |
Probability |
Impact |
Mitigation |
| Gastrointestinal effects |
Medium |
Low |
Dose titration |
| Drug interactions |
Low |
Medium |
Review concomitant meds |
| Nutritional decline |
Medium |
Medium |
Dietician support |
-
20% withdrawal due to GI: Modify dose
- Clear efficacy: Early termination
- Safety signal: Review by DSMB
Metabolic targeting in ALS informs:
- Metabolic approaches in AD
- Energy dysfunction in PD
- General metabolic therapy frameworks
- Pagano et al., Metabolic dysfunction in ALS (2018)
- Dupuis et al., Energy metabolism in neurodegenerative diseases (2021)
- Werth et al., Lipid metabolism alterations in ALS (2024)
- Kim et al., Glucose intolerance in ALS (2024)
- Ferrari et al., ALS and metabolic disorders (2019)